Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2023
Equity and obesity treatment - expanding Medicaid covered interventions
22 June 2023 - In medicine, the media, and the public sphere, the cause of obesity is often oversimplified as ...
Posted by Michael Wonder on 24 May 2023
Medicaid plans to audit the prices of costliest drugs
23 May 2023 - The Biden administration said Tuesday it is planning to conduct a yearly audit to verify the ...
Posted by Michael Wonder on 23 May 2023
Biden-Harris Administration announces proposal to advance prescription drug transparency in Medicaid
23 May 2023 - New HHS proposal would shed light on cost of prescription drugs and save states and federal ...
Posted by Michael Wonder on 12 Mar 2023
By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates
6 March 2023 - Eli Lilly would’ve had to pay Medicaid about $150 for each vial of insulin used in ...
Posted by Michael Wonder on 20 Sep 2022
The US Medicaid program: coverage, financing, reforms, and implications for health equity
20 September 2022 - In 2022, Medicaid insured approximately 80.6 million individuals (56.4% from racial and ethnic minority groups in 2019). ...
Posted by Michael Wonder on 20 Jul 2022
For Medicaid insured patients with cancer, health insurance does not always mean health access
15 July 2022 - Although there has been a significant increase in the number of U.S. residents insured through Medicaid since ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 08 May 2022
Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs
7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...
Posted by Michael Wonder on 18 Apr 2022
Risks to the 340B drug pricing program related to manufacturer restrictions on drug availability
15 April 2022 - On 21 March 2022, Johnson & Johnson became the 16th pharmaceutical manufacturer to restrict the delivery of ...
Posted by Michael Wonder on 17 Oct 2021
Recent trends in Medicaid spending and use of drugs with US Food and Drug Administration accelerated approval
8 October 2021 - In this cross-sectional study of 216 drugs granted accelerated approval from 1992 through 2020, relative to all ...
Posted by Michael Wonder on 21 Jun 2021
Health equity and Medicaid transformation — operationalising President Biden’s agenda
19 June 2021 - President Biden has made reforms intended to “protect and strengthen Medicaid” a centrepiece of his health policy ...
Posted by Michael Wonder on 28 Oct 2020
Medicare and Medicaid to cover early COVID-19 vaccine
26 October 2020 - The new regulations would allow beneficiaries to receive a vaccine under “emergency authorisation” at no cost. ...
Posted by Michael Wonder on 12 Aug 2020
CMS proposes changes to Medicaid best price rule: a potential boost to value-based contracting
9 August 2020 - For well over a decade policymakers have declared the healthcare system is moving towards value-based pricing ...
Posted by Michael Wonder on 22 Jun 2020
Trump Administration proposes Medicaid reforms to encourage innovative contracting models
22 June 2020 - On Wednesday, June 17, the Centers for Medicare and Medicaid Services proposed a series of reforms ...
Posted by Michael Wonder on 02 Jun 2020
Estimating the cost of delayed generic drug entry to Medicaid
1 June 2020 - Delays in market entry of generic drugs are common. ...